The Health Resources and Services Administration today released a proposed rule that would implement an Affordable Care Act provision requiring a binding administrative dispute resolution process for 340B Drug Pricing Program participants who claim they have been overcharged for drugs purchased through the program. Under the proposed process, which also would be available to drug manufacturers, a decision-making body within the Department of Health and Human Services would review and resolve the claims. The proposed rule will be published in the Aug. 12 Federal Register with comments accepted through Oct. 11. AHA staff are reviewing the rule, and member hospitals that are 340B participants will receive more information.

Related News Articles

Headline
The AHA today urged the Centers for Medicare…
Headline
The AHA Friday shared recommendations for developing a unified post-acute care prospective payment system as required by the Improving Medicare Post-Acute Care…
Insights and Analysis
As the 2019 chair of the AHA’s Section for Small or Rural Hospitals, I can attest that AHA is stepping up in a big way to grapple with the issues that affect…
Headline
The Centers for Medicare…
Headline
The Department of Health and Human Services’ Center for Medicare and Medicaid Innovation today announced a new payment model for emergency ambulance services…
Headline
The AHA today expressed support for the Resident Physician Shortage Reduction Act, legislation that would add 15,000 Medicare-funded residency positions over…